Charles River Laboratories International (NYSE:CRL) Stock Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Charles River Laboratories International, Inc. NYSE: CRL. In a filing disclosed on May 08th, the Representative disclosed that they had bought between $15,001 and $50,000 in Charles River Laboratories International stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
• Sold $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 4/16/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 4/11/2025.
• Sold $1,001 - $15,000 in shares of Western Digital NASDAQ: WDC on 4/10/2025.
• Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
• Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.

Charles River Laboratories International Stock Performance

CRL traded down $1.73 during trading hours on Tuesday, hitting $141.35. The company's stock had a trading volume of 152,698 shares, compared to its average volume of 1,539,497. The company has a 50-day simple moving average of $137.91 and a 200 day simple moving average of $165.93. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $6.94 billion, a PE ratio of 942.35, a PEG ratio of 4.54 and a beta of 1.50. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same period last year, the company earned $2.27 earnings per share. The company's quarterly revenue was down 2.7% compared to the same quarter last year. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on CRL shares. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 target price on the stock in a report on Monday, March 3rd. William Blair downgraded Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 22nd. Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price for the company in a research note on Thursday, May 8th. Mizuho dropped their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th. Finally, Robert W. Baird raised their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and a consensus target price of $176.00.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. This trade represents a 18.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company's stock.

Institutional Trading of Charles River Laboratories International

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rothschild Investment LLC lifted its stake in Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after acquiring an additional 144 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares in the last quarter. HM Payson & Co. purchased a new stake in shares of Charles River Laboratories International in the first quarter worth approximately $31,000. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares in the last quarter. Finally, Optiver Holding B.V. purchased a new position in Charles River Laboratories International during the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 98.91% of the company's stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).